Gene
KCNJ5
KCNJ5 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (1), Actionable biomarkers (2), Trial mentions (1), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention KCNJ5. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
KCNJ5 has 1 trial mention across 1 year. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 3 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 3 of 13,598 | 0.02% |
| 2021 | 0 of 8,692 | 0.00% | 4 of 15,045 | 0.03% |
| 2020 | 0 of 7,640 | 0.00% | 5 of 14,459 | 0.03% |
| 2019 | 0 of 7,300 | 0.00% | 1 of 12,159 | 0.01% |
| 2018 | 0 of 6,927 | 0.00% | 4 of 11,854 | 0.03% |
| 2017 | 0 of 6,558 | 0.00% | 10 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (1)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Transgenomic | Diagnostic provider | Clinical validation | 1 | October 01, 2018 |
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| KCNJ5 (L168R) | VERAPAMIL | response-associated | adrenocortical adenoma | Cancer Genome Interpreter |
| KCNJ5 (L168R) | Amiloride | response-associated | adrenocortical adenoma | Cancer Genome Interpreter |
Trial mentions (1)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02945904 | Trial biospecimen (AACT) |
Target-disease associations (267)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal blistering of the skin | phenotype | GWAS credible sets |
| Abnormality of the cardiovascular system | phenotype | Variant curation (ClinVar / EVA) |
| Andersen-Tawil syndrome | genetic, familial or congenital disease | Literature (Europe PMC) |
| Andersen-Tawil syndrome | genetic, familial or congenital disease | orphanet |
| Arrhythmogenic right ventricular dysplasia | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 267 associations.
Vendor sourcing (23)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein functio... | View ClinVar record SCV000319802.7 |
| Barts and the London School of Medicine and Dentistry W Smithfield London - City of London EC1A 7BE | Trial collaborator | Biospecimen collected in a trialTrial biospecimen collection | No supporting text recorded; see the citation. | View trial NCT02945904 |
| Barts and the London School of Medicine and Dentistry W Smithfield London - City of London EC1A 7BE | Trial collaborator | Mentioned in trial textTrial free-text mention | KCNJ5 | View trial NCT02945904 |
| DASA (Brazil) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | NM_000890.5(KCNJ5):c.616G>A (p.Ala206Thr) is a missense variant that results in the substitution of alanine with threonine. This variant is rare in populatio... | View ClinVar record SCV007667465.2 |
| GeneDx Holdings Corp. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserv... | View ClinVar record SCV000169928.12 |
Showing 5 of 23 sourcing records.
Trial-cited literature (39)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| [<sup>11</sup>C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial. | Nature medicine | 2023 | 114 |
| Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism: The ADOPA Randomized Clinical Trial. | JAMA network open | 2023 | 23 |
| Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes. | Endocrine connections | 2023 | 21 |
| Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. | Endocrine pathology | 2022 | 269 |
| Co-Occurrence of Tic Disorders and Attention-Deficit/Hyperactivity Disorder-Does It Reflect a Common Neurobiological Background? | Biomedicines | 2022 | 12 |
Showing 5 of 39 papers.
Protein variant mentions (30)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A206T | 1 | 2015 | PMID 25741868 |
| p.A396T | 1 | 2015 | PMID 25741868 |
| p.D123N | 1 | 2015 | PMID 25741868 |
| p.D395A | 1 | 2015 | PMID 25741868 |
| p.E145K | 1 | 2023 | PMID 36646800 |
Showing 5 of 30 variants.
Literature-extracted relations (25)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Aldosterone | Chemical | positive_correlate |
Cortisol Co-Secretion and Clinical Usefulness of ACTH Stimulation Test in Primary Aldosteronism: A Systematic Review and Biases in Epidemiological Studies. | 2021 |
| Aldosterone | Chemical | associate |
Tumor Cell Subtypes Based on the Intracellular Hormonal Activity in KCNJ5-Mutated Aldosterone-Producing Adenoma. | 2018 |
| lipids | Chemical | associate |
Tumor Cell Subtypes Based on the Intracellular Hormonal Activity in KCNJ5-Mutated Aldosterone-Producing Adenoma. | 2018 |
| Aldosterone | Chemical | associate |
Macrolides Blunt Aldosterone Biosynthesis: A Proof-of-Concept Study in <i>KCNJ5</i> Mutated Adenoma Cells Ex Vivo. | 2017 |
| Clarithromycin | Chemical | associate |
Macrolides Blunt Aldosterone Biosynthesis: A Proof-of-Concept Study in <i>KCNJ5</i> Mutated Adenoma Cells Ex Vivo. | 2017 |
Showing 5 of 25 relation assertions.
Organizations publishing (131)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Harvard Medical School | Academic | 3 | 2020 to 2021 |
| Mayo Clinic | Hospital | 3 | 2013 to 2022 |
| University of Turin | Academic | 3 | 2020 to 2022 |
| Mass General Brigham | Hospital | 2 | 2020 to 2021 |
| University of Ottawa | Academic | 2 | 2021 |
Showing 5 of 131 organizations.
Where KCNJ5 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
236 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.